Milite Ciro, Feoli Alessandra, Sasaki Kazuki, La Pietra Valeria, Balzano Amodio Luca, Marinelli Luciana, Mai Antonello, Novellino Ettore, Castellano Sabrina, Tosco Alessandra, Sbardella Gianluca
†Epigenetic Med Chem Lab, Dipartimento di Farmacia, Università degli Studi di Salerno, Via Giovanni Paolo II 132, I-84084 Fisciano, Salerno, Italy.
‡Chemical Genetics Laboratory, RIKEN Advanced Science Institute, Wako, Saitama 351-0198, Japan.
J Med Chem. 2015 Mar 26;58(6):2779-98. doi: 10.1021/jm5019687. Epub 2015 Mar 10.
Selective inhibitors of the two paralogue KAT3 acetyltransferases (CBP and p300) may serve not only as precious chemical tools to investigate the role of these enzymes in physiopathological mechanisms but also as lead structures for the development of further antitumor agents. After the application of a molecular pruning approach to the hardly optimizable and not very cell-permeable garcinol core structure, we prepared many analogues that were screened for their inhibitory effects using biochemical and biophysical (SPR) assays. Further optimization led to the discovery of the benzylidenebarbituric acid derivative 7h (EML425) as a potent and selective reversible inhibitor of CBP/p300, noncompetitive versus both acetyl-CoA and a histone H3 peptide, and endowed with good cell permeability. Furthermore, in human leukemia U937 cells, it induced a marked and time-dependent reduction in the acetylation of lysine H4K5 and H3K9, a marked arrest in the G0/G1 phase and a significant increase in the hypodiploid nuclei percentage.
两种同源KAT3乙酰转移酶(CBP和p300)的选择性抑制剂不仅可作为研究这些酶在生理病理机制中作用的珍贵化学工具,还可作为开发进一步抗肿瘤药物的先导结构。在对难以优化且细胞通透性不佳的藤黄菌素核心结构应用分子剪枝方法后,我们制备了许多类似物,并使用生化和生物物理(SPR)测定法筛选它们的抑制作用。进一步优化导致发现苄叉巴比妥酸衍生物7h(EML425),它是一种有效且选择性的CBP/p300可逆抑制剂,对乙酰辅酶A和组蛋白H3肽均无竞争性,且具有良好的细胞通透性。此外,在人白血病U937细胞中,它可诱导赖氨酸H4K5和H3K9乙酰化显著且随时间依赖性降低,在G0/G1期显著停滞,并使亚二倍体核百分比显著增加。